Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

Affiliation auteurs!!!! Error affiliation !!!!
TitrePembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
Type de publicationJournal Article
Year of Publication2021
AuteursChoueiri TK, Tomczak P, Park SHoon, Venugopal B, Ferguson T, Chang Y-H, Hajek J, Symeonides SN, Lee J-L, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Zhang E(Pingye), Rogerio JWillemann, Imai K, Quinn DI, Powles T
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume39
Date PublishedJUN 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2021.39.15_suppl.LBA5